San Diego-centered Viking Therapeutics marked alone as a serious competitor within the weight loss drug market place in February soon after revealing promising data from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection and in March the company